ES2073533T3 - Uso antivirico de composiciones que constan de acidos grasos esenciales e interferon. - Google Patents

Uso antivirico de composiciones que constan de acidos grasos esenciales e interferon.

Info

Publication number
ES2073533T3
ES2073533T3 ES90308542T ES90308542T ES2073533T3 ES 2073533 T3 ES2073533 T3 ES 2073533T3 ES 90308542 T ES90308542 T ES 90308542T ES 90308542 T ES90308542 T ES 90308542T ES 2073533 T3 ES2073533 T3 ES 2073533T3
Authority
ES
Spain
Prior art keywords
antivirical
interfered
fatty acids
essential fatty
compositions consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90308542T
Other languages
English (en)
Inventor
David Frederick Horrobin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Application granted granted Critical
Publication of ES2073533T3 publication Critical patent/ES2073533T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

EL USO DE UNO O MAS ACIDOS GANMA LINOLENICO ACIDO DIHOMO-LINOLICO ACIDO ARACHIDONICO PARA LA CONFECION DE UN MEDICAMENTO USADO PARA INCREMENTAR LOS EFECTOS DEL INTERFEROM EN LA ANTI VIRICA, ANTI CANCER O ANTI-INFLAMATORIA DICHO MEDICAMENTO ES USADO CON UN MEDICAMENTO QUE CONTIENE UNO O MAS INTERFERONES NO SOLAMENTE PARA INCREMENTAR LOS EFECTOS DE INTERFERONES ANDOGENOS.
ES90308542T 1989-08-10 1990-08-02 Uso antivirico de composiciones que constan de acidos grasos esenciales e interferon. Expired - Lifetime ES2073533T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898918294A GB8918294D0 (en) 1989-08-10 1989-08-10 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ES2073533T3 true ES2073533T3 (es) 1995-08-16

Family

ID=10661451

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90308542T Expired - Lifetime ES2073533T3 (es) 1989-08-10 1990-08-02 Uso antivirico de composiciones que constan de acidos grasos esenciales e interferon.

Country Status (15)

Country Link
US (1) US5580556A (es)
EP (2) EP0678299A3 (es)
AT (1) ATE123948T1 (es)
AU (1) AU633603B2 (es)
CA (1) CA2022608A1 (es)
DE (1) DE69020267T2 (es)
DK (1) DK0416743T3 (es)
ES (1) ES2073533T3 (es)
GB (1) GB8918294D0 (es)
GR (1) GR3016980T3 (es)
HK (1) HK53496A (es)
IE (1) IE67773B1 (es)
NO (1) NO903509L (es)
NZ (1) NZ234786A (es)
ZA (1) ZA906187B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP4172726B2 (ja) * 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
AU2002305099A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty alcohol drug conjugates
AU2002303164A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
CA2436650A1 (en) 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US10471131B2 (en) 2012-01-19 2019-11-12 Hybrid Medical, Llc Topical therapeutic formulations
EP2804606B1 (en) 2012-01-19 2017-06-28 Hybrid Medical, LLC Topical therapeutic formulations
MX2016015961A (es) 2014-06-04 2017-04-05 Dignity Sciences Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2967049D1 (en) * 1978-04-11 1984-07-19 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
AU1933383A (en) * 1982-09-22 1984-03-29 Sentrachem Limited Composition of prostaglandins for prevention of cancer
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
IE63225B1 (en) * 1988-09-13 1995-04-05 Efamol Holdings Use of fatty acids in the treatment of myalgic encephalomyelitis

Also Published As

Publication number Publication date
DE69020267T2 (de) 1996-01-25
NO903509D0 (no) 1990-08-09
HK53496A (en) 1996-04-03
IE902774A1 (en) 1991-02-27
NZ234786A (en) 1997-06-24
EP0678299A3 (en) 1998-11-04
DE69020267D1 (de) 1995-07-27
NO903509L (no) 1991-02-11
EP0678299A2 (en) 1995-10-25
GR3016980T3 (en) 1995-11-30
IE67773B1 (en) 1996-04-17
AU633603B2 (en) 1993-02-04
GB8918294D0 (en) 1989-09-20
AU6017890A (en) 1991-02-14
EP0416743A1 (en) 1991-03-13
CA2022608A1 (en) 1991-02-11
EP0416743B1 (en) 1995-06-21
US5580556A (en) 1996-12-03
DK0416743T3 (da) 1995-08-14
ATE123948T1 (de) 1995-07-15
ZA906187B (en) 1991-06-26

Similar Documents

Publication Publication Date Title
ES2073533T3 (es) Uso antivirico de composiciones que constan de acidos grasos esenciales e interferon.
GR3006068T3 (es)
SE8902701L (sv) Fettsyrakomposition
DE3486235T2 (de) Fettsäure-Zusammensetzungen.
NL191332B (nl) Farmaceutisch preparaat met de ethylester van (all-Z)-5,8,11,14,17-eicosapentaeenzuur.
ES2107622T3 (es) Medicamento para el tratamiento de la distrofia vulvar o la sequedad vaginal.
DE3875286D1 (de) Essentielle fettsaeure enthaltende zusammensetzungen.
ATE22532T1 (de) Pharmazeutische zusammensetzung.
TW223589B (es)
ATE19855T1 (de) Pharmazeutische und diaetetische zusammensetzung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 416743

Country of ref document: ES